[go: up one dir, main page]

PL2350026T3 - Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek - Google Patents

Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek

Info

Publication number
PL2350026T3
PL2350026T3 PL09778874T PL09778874T PL2350026T3 PL 2350026 T3 PL2350026 T3 PL 2350026T3 PL 09778874 T PL09778874 T PL 09778874T PL 09778874 T PL09778874 T PL 09778874T PL 2350026 T3 PL2350026 T3 PL 2350026T3
Authority
PL
Poland
Prior art keywords
medicine
manufacture
pyrimidine derivatives
substituted aniline
cdk inhibitors
Prior art date
Application number
PL09778874T
Other languages
English (en)
Inventor
Ulrich Lücking
Rolf Jautelat
Gerhard Siemeister
Julia Schulze
Philip Lienau
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PL2350026T3 publication Critical patent/PL2350026T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL09778874T 2008-10-21 2009-10-09 Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek PL2350026T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2009/007247 WO2010046035A1 (de) 2008-10-21 2009-10-09 Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel
EP09778874.9A EP2350026B1 (de) 2008-10-21 2009-10-09 Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel

Publications (1)

Publication Number Publication Date
PL2350026T3 true PL2350026T3 (pl) 2014-11-28

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09778874T PL2350026T3 (pl) 2008-10-21 2009-10-09 Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek

Country Status (38)

Country Link
US (1) US8735412B2 (pl)
EP (2) EP2179991A1 (pl)
JP (1) JP5564054B2 (pl)
KR (1) KR20110069115A (pl)
CN (1) CN102197029B (pl)
AR (1) AR074053A1 (pl)
AU (1) AU2009306733C1 (pl)
BR (1) BRPI0920112A2 (pl)
CA (1) CA2739739C (pl)
CO (1) CO6361926A2 (pl)
CR (1) CR20110210A (pl)
CU (1) CU24052B1 (pl)
CY (1) CY1115590T1 (pl)
DK (1) DK2350026T3 (pl)
DO (1) DOP2011000107A (pl)
EA (1) EA019230B1 (pl)
EC (1) ECSP11010992A (pl)
ES (1) ES2499028T3 (pl)
HN (1) HN2011001019A (pl)
HR (1) HRP20140830T1 (pl)
IL (1) IL211713A (pl)
MA (1) MA32723B1 (pl)
MX (1) MX2011004238A (pl)
MY (1) MY155230A (pl)
NZ (1) NZ592314A (pl)
PA (1) PA8846201A1 (pl)
PE (1) PE20110546A1 (pl)
PL (1) PL2350026T3 (pl)
PT (1) PT2350026E (pl)
RS (1) RS53523B1 (pl)
SA (1) SA109300632B1 (pl)
SI (1) SI2350026T1 (pl)
TN (1) TN2011000199A1 (pl)
TW (2) TWI458716B (pl)
UA (1) UA103500C2 (pl)
UY (1) UY32190A (pl)
WO (1) WO2010046035A1 (pl)
ZA (1) ZA201103727B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
EP2755948B1 (en) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
KR20140135215A (ko) * 2012-03-21 2014-11-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 특정한 종양의 치료를 위한 (rs)-s-시클로프로필-s-(4-{[4-{[(1r, 2r)-2-히드록시-1-메틸프로필]옥시}-5-(트리플루오로메틸)피리미딘-2-일]아미노}페닐)술폭시미드의 용도
CA2964696C (en) * 2014-10-16 2022-09-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
PT3849537T (pt) 2018-09-10 2025-01-22 Mirati Therapeutics Inc Terapêuticas de combinação
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
ES2253821T3 (es) 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
EP1483260A1 (de) * 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2008514571A (ja) * 2004-09-29 2008-05-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換2−置換アニリノピリミジン類、それらの製造および薬剤としての使用
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
TWI496774B (zh) 2015-08-21
BRPI0920112A2 (pt) 2015-12-22
JP2012506391A (ja) 2012-03-15
PE20110546A1 (es) 2011-08-12
HN2011001019A (es) 2013-07-01
CN102197029A (zh) 2011-09-21
CU20110088A7 (es) 2011-12-28
TWI458716B (zh) 2014-11-01
NZ592314A (en) 2013-02-22
IL211713A (en) 2015-04-30
TW201020237A (en) 2010-06-01
PA8846201A1 (es) 2010-05-26
MY155230A (en) 2015-09-30
US20110294838A1 (en) 2011-12-01
AU2009306733A1 (en) 2010-04-29
CN102197029B (zh) 2014-05-14
WO2010046035A1 (de) 2010-04-29
ES2499028T3 (es) 2014-09-26
SA109300632B1 (ar) 2013-07-04
IL211713A0 (en) 2011-06-30
ZA201103727B (en) 2014-11-26
MA32723B1 (fr) 2011-10-02
CR20110210A (es) 2011-06-08
MX2011004238A (es) 2011-05-23
PT2350026E (pt) 2014-09-12
KR20110069115A (ko) 2011-06-22
CY1115590T1 (el) 2017-01-04
ECSP11010992A (es) 2011-05-31
AR074053A1 (es) 2010-12-22
TN2011000199A1 (en) 2012-12-17
CA2739739C (en) 2016-12-20
EP2350026A1 (de) 2011-08-03
UA103500C2 (uk) 2013-10-25
CO6361926A2 (es) 2012-01-20
HRP20140830T1 (hr) 2014-11-21
EA201100623A1 (ru) 2011-12-30
UY32190A (es) 2010-05-31
AU2009306733B2 (en) 2015-11-12
RS53523B1 (sr) 2015-02-27
DOP2011000107A (es) 2011-05-15
TW201444803A (zh) 2014-12-01
DK2350026T3 (da) 2014-09-15
AU2009306733C1 (en) 2016-07-14
CU24052B1 (es) 2014-12-26
EA019230B1 (ru) 2014-02-28
EP2350026B1 (de) 2014-06-18
EP2179991A1 (de) 2010-04-28
JP5564054B2 (ja) 2014-07-30
SI2350026T1 (sl) 2014-10-30
US8735412B2 (en) 2014-05-27
CA2739739A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
PL2350026T3 (pl) Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
AU2009276339A8 (en) Pyrimidine compounds, compositions and methods of use
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL207195A0 (en) Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof
IL210176A0 (en) Substituted pyrimidone derivatives
AP2010005390A0 (en) Crystal form of phenylamino pyrimidine derivatives.
IL212070A (en) Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone
ZA201008387B (en) Azacarboline derivatives,preparation thereof,and therapeutic use thereof as kinase inhibitors
EP2365809B8 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL210869A (en) Derivatives of imidaziadiazoles, their process, preparation, uses and medications containing them
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
EP2184277A4 (en) ARYLPYRIMIDINE DERIVATIVES, METHODS OF PREPARATION AND PHARMACEUTICAL USES OF THE DERIVATIVES
PL2448927T3 (pl) Nowe pochodne (6-okso-1,6-dihydro-pirymidyn-2-ylo)-amidu, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
ZA201105219B (en) (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
ZA201204339B (en) Novel (heterocycle-tetrahydropyridine)(piperazinyl)-1-alcanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alcanone derivatives,and use thereof as p75 inhibitors
ZA201203631B (en) New phenylhydrazone derivatives and their use as pharmaceuticals
IL217351A0 (en) 2-amino-2-phenyl-alkanol derivatives, prepartion thereof, and pharmaceutical compositons containing same
FI20070306A0 (fi) Eläimiä karkottava, hajua vapauttava stabiili koostumus sitä sisältävä tuote ja menetelmä eläinten karkottamiseksi
HK1163691A (en) Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
HK1175784A (en) Novel (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
FI20080007A0 (fi) Uudet rakeet, tabletit ja valmistusmenetelmä